Seizure and Prison for Owner of Immuno Biotec
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
After a four-year investigation by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) (and with the support of the London Regional Asset Recovery Team, RART), the owner of Guernsey-based Immuno Biotech is now facing a £1.4 million seizure, including private property.
He has already served a 15-month prison sentence based on four counts of manufacturing, selling and supplying an unlicensed drug (plus one for money laundering).
Immuno Biotech was a distributor of a human blood product called Globulin component Macrophage Activating Factor (GcMAF). GcMAF was advertised and sold over the Internet as a so-called "miracle cure" for various diseases and conditions. Following an investigation, the MHRA confiscated more than 10,000 vials of the product and issued a warning to the public.
Source: GOV.UK provided by the Government Digital Service.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years